Member Posts > Cardiol Therapeutics to Present Pioneering Cardiovascular Therapies at TD Cowen Health Care Conference
Cardiol Therapeutics Inc., a clinical-stage biotechnology company specializing in developing anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation, scheduled for March 5, 2025, at 11:10 AM EST in Boston, will provide a platform to showcase its latest advancements in cardiac treatment to investors, industry leaders, and medical professionals.
This announcement is part of Cardiol Therapeutics' ongoing strategy to engage with key stakeholders and highlight its innovative research. The company has a history of leveraging industry conferences to share developments. On February 11, 2025, it took part in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, presenting updates on its clinical programs targeting heart disease. Likewise, on September 26, 2023, CEO David Elsley provided a detailed overview of the company's vision and pipeline at the Cantor Fitzgerald 2023 Global Healthcare Conference.
Cardiol Therapeutics' consistent participation in major events reaffirms its dedication to developing transformative cardiovascular therapies aimed at improving patient outcomes and reshaping the future of heart disease treatment.

#CardiolTherapeutics #BiotechNews #HeartHealth #PharmaInnovation #InvestorRelations #MedicalBreakthroughs